Iovance Biotherapeutics, Inc.
IOVA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $264M | $164M | +60.6% |
| Operating income | −$403M | −$395M | −2.0% |
| Net income | −$391M | −$372M | −5.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $122M | $67.5M | +80.0% |
| Operating income | −$24.0M | −$94.9M | +74.7% |
| Net income | −$22.3M | −$91.3M | +75.6% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Iovance's revenue in FY2025?
- $264M in FY2025 (Fiscal year ended Dec 31, 2025), +60.6% vs $164M a year earlier, per its 10-K filed Feb 2026.
- Was Iovance profitable in FY2025?
- No: net income was −$391M and operating income −$403M in FY2025.
- What was Iovance's revenue in Q3 2026?
- $122M (+80.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.